Compare Accenture plc (ACN) vs Pfizer Inc (PFE) Price & Performance

Accenture (ACN) trades at $178.25, up 1.44% with strong technical and fundamental momentum. The stock shows bullish technical signals with support at $174 and resistance at $181, while recent earnings consistently beat expectations with Q1 2026 EPS of $3.80 versus $3.70 expected. Revenue growth accelerated to $69.67 billion in 2025, with solid profitability margins and attractive valuation metrics including P/E of 14.36. Recent partnerships with TEPCO and AlphaSense highlight ongoing AI-driven business transformation initiatives.

Outlook remains positive with analyst consensus price target of $189.77 offering 6.5% upside potential. Key opportunities include continued AI adoption and margin expansion, while risks involve competitive pressures and potential economic slowdown affecting consulting demand. The strong buy rating consensus (66% of analysts) supports continued investor confidence in the company's growth trajectory.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.